Literature DB >> 28472499

A pharmacy management service for adults with asthma: a cluster randomised controlled trial.

Lai-Yan Wong1,2, Siew-Siang Chua1, Abdul-Rahman Husin3, Hanisah Arshad4.   

Abstract

Background: Although clinical guidelines are available for the management of asthma, this health condition is still poorly managed in many countries.
Objectives: To assess the effects of a Pharmacy Management Service (PharMS) on asthma control of adult patients.
Methods: This study comprised of a cluster randomised controlled trial (RCT) that was conducted from April 2014 to July 2015 at four government health clinics. The control participants received usual pharmacy service, while the intervention participants were recruited into the PharMS. Each participant was monitored for 6 months, and the outcome measures included asthma control using the Asthma Control Test (ACT), inhaler technique using a checklist and medication adherence using the Malaysian Medication Adherence Scale.
Results: A total of 157 participants were recruited: 77 in the control and 80 in the intervention group. At the end of the study, 90% of the intervention participants achieved well-controlled asthma compared to 28.6% in the control group (P < 0.001). The differences in the proportion of participants with correct inhaler technique was also significant, with an adjusted effect size of 0.953 (P < 0.001). In addition, the intervention participants showed significantly higher medication adherence than the control group (92.5% versus 45.5%, P < 0.001). The Generalised Estimated Equation analysis further confirmed that the PharMS (P < 0.001) was significantly related to an improvement in the ACT scores.
Conclusion: A community-based asthma management program, the PharMS, that provided asthma education and skill training by a trained pharmacist, resulted in positive and significant improvements in clinical and management outcomes of adult asthma patients.
© The Author 2017. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Asthma; inhaler technique; medication adherence; pharmaceutical care; pharmacist; randomised controlled trial

Mesh:

Year:  2017        PMID: 28472499     DOI: 10.1093/fampra/cmx028

Source DB:  PubMed          Journal:  Fam Pract        ISSN: 0263-2136            Impact factor:   2.267


  5 in total

1.  In-Patient Pulmonary Rehabilitation to Improve Asthma Control–A Randomized Controlled Study (EPRA, Effectiveness of Pulmonary Rehabilitation for Patients with Asthma).

Authors:  Konrad Schultz; Michael Wittmann; Rupert Wagner; Nicola Lehbert; Larissa Schwarzkopf; Boglárka Szentes; Dennis Nowak; Hermann Faller; Michael Schuler
Journal:  Dtsch Arztebl Int       Date:  2021-01-22       Impact factor: 5.594

2.  Clinical and other specialty services offered by pharmacists in the community: the international arena and Israel.

Authors:  Eyal Schwartzberg; Joseph P Nathan; Sivan Avron; Eli Marom
Journal:  Isr J Health Policy Res       Date:  2018-12-01

3.  COPD Management in Community Pharmacy Results in Improved Inhaler Use, Immunization Rate, COPD Action Plan Ownership, COPD Knowledge, and Reductions in Exacerbation Rates.

Authors:  Mariam Fathima; Zeeta Bawa; Bernadette Mitchell; Juliet Foster; Carol Armour; Bandana Saini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-03-02

4.  Implementing asthma management guidelines in public primary care clinics in Malaysia.

Authors:  Ai Theng Cheong; Ping Yein Lee; Sazlina Shariff-Ghazali; Hani Salim; Norita Hussein; Rizawati Ramli; Hilary Pinnock; Su May Liew; Nik Sherina Hanafi; Ahmad Ihsan Abu Bakar; Azainorsuzila Mohd Ahad; Yong Kek Pang; Karuthan Chinna; Ee Ming Khoo
Journal:  NPJ Prim Care Respir Med       Date:  2021-11-29       Impact factor: 2.871

5.  Medication adherence in Medicare-enrolled older adults with asthma before and during the coronavirus disease 2019 pandemic.

Authors:  Olivia L Ramey; Armando Silva Almodóvar; Milap C Nahata
Journal:  Ann Allergy Asthma Immunol       Date:  2022-02-25       Impact factor: 6.248

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.